Fig. 1

ANLN was upregulated in pancreatic cancer. a, ANLN expression was significantly upregulated in 174 pancreatic cancer tissues compared with that in 62 normal tissues (P < 0.001, http://medical-genome.kribb.re.kr/GENT/). b, The genetic alteration frequency of ANLN was evaluated in four independent cohorts (QCMG, Nature 2016; TCGA, PanCancer Atlas; TCGA, Provisional; UTSW, Nat Commun) from cBioportal for Cancer Genomic (www.cbioportal.org/). c, Genetic abnormalities of the copy number of the ANLN gene were plotted in two pancreatic cancer datasets (Pancreatic Adenocarcinoma-TCGA, PanCancer Atlas and Pancreatic Adenocarcinoma-TCGA, Provisional) from cBioportal for Cancer Genomic (www.cbioportal.org/). d, The association between ANLN expression in pancreatic cancers and survival time was analyzed by Kaplan–Meier survival analysis in the Human Protein Atlas (www.proteinatlas.org/). e, Representative photomicrographs from ANLN IHC staining of eighty pancreatic cancer tissues and ten cancer-adjacent normal tissues are shown in the upper panel (× 200 and × 400 magnification). Kaplan-Meier survival curve of the overall survival according to high and low ANLN expression in pancreatic cancer tissues is shown in the lower panel (P < 0.001). f, The ANLN protein expression levels were increased in five pancreatic cancer cell lines (AsPC-1, PANC-1, BxPC-3, MIA PaCa-2 and SW1990) compared with those in the hTERT-HPNE cell line. **, P < 0.01 compared with the hTERT-HPNE cell line